Using Transcriptomics to Predict Glycan Profiles in Biopharmaceuticals
Author Information
Author(s): Ben West, Pavlos Kotidis, Alena Istrate, Daniele Perna, Gary Finka, A. Jamie Wood, Daniel Ungar
Primary Institution: University of York and GlaxoSmithKline Research and Development
Hypothesis
Can transcriptomic data predict glycosylation outcomes in monoclonal antibody production?
Conclusion
The study found that transcriptomic data can help predict glycosylation profiles, which are crucial for the efficacy of therapeutic antibodies.
Supporting Evidence
- Transcriptomic data can predict glycosylation trends in monoclonal antibodies.
- Alg5 levels can indicate the potential for higher therapeutic efficacy in mAbs.
- Early-stage transcriptomics can guide adjustments in cell line development.
Takeaway
Scientists can look at the genes in cells to guess how well the sugars on medicines will work, helping to make better medicines faster.
Methodology
The study used bulk RNA sequencing and glycan profiling to analyze gene expression and glycan structures in monoclonal antibody production.
Potential Biases
Potential biases may arise from the reliance on transcriptomic data, which does not always correlate with protein levels or activity.
Limitations
The relationship between transcriptomic data and glycosylation outcomes is complex and not straightforward.
Participant Demographics
Cell lines used were from biopharmaceutical production processes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website